How To Compare Quality of Life of Breast Cancer Patients in Clinical Trials
Quality of life of breast cancer patients receiving systemic therapy has been studied in advanced disease when treatments are given with palliative intent [1–3]. In the adjuvant setting, however, therapies associated with acute toxic effects are administered during a time when patients are free of disease-related symptoms . The expectation is that the investment of this period of toxicity will be balanced by a delay in relapse and improvement in survival for the future. The toxic effects are felt by the entire population of patients, while it is possible that the benefits of treatment might be enjoyed by only some.
KeywordsToxicity Estrogen Oncol Methotrexate Tamoxifen
Unable to display preview. Download preview PDF.
- 12.Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes RJ, for the International Breast Cancer Study Group (1992) Quality of life in clinical trials of adjuvant therapies. Natl Cancer Inst Monogr 11:127–135Google Scholar